A Study Assessing The Real-World Efficacy And Safety Of Paritaprevir/Ritonavir, Ombitasvir And Dasabuvir (PrOD) ± Ribavirin In Elderly Patients With Hepatitis-C Virus Infection (HCV) Genotype 1b Compensated Cirrhosis

Trial Profile

A Study Assessing The Real-World Efficacy And Safety Of Paritaprevir/Ritonavir, Ombitasvir And Dasabuvir (PrOD) ± Ribavirin In Elderly Patients With Hepatitis-C Virus Infection (HCV) Genotype 1b Compensated Cirrhosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 May 2017

At a glance

  • Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 May 2017 New trial record
    • 09 May 2017 Results presented at the Digestive Disease Week 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top